Clinical Trial: KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07652879) titled 'KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome' on May 24.

Brief Summary: This study is a single-center, prospective, open-label clinical study to evaluate the efficacy and safety of KCD(Carfilzomib/Cyclophosphamide/Dexamethasone) regimen in subjects with newly diagnosed POEMS Syndrome.

Study Start Date: June 15

Study Type: INTERVENTIONAL

Condition: POEMS Syndrome

Intervention: DRUG: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE

carfilzomib at a dose of 27 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15,cyclophosphamide at a dose ...